Teriparatide:审查。

文章的细节

引用
复制到剪贴板

Quattrocchi E, Kourlas H

Teriparatide:审查。

其他。2004年6月,26 (6):841 - 54。doi: 10.1016 / s0149 - 2918 (04) 90128 - 2。

PubMed ID
15262455 (在PubMed
]
文摘

背景:传统上,男性和女性的骨质疏松症的管理包括开出抗再吸收剂的使用结合钙和维生素D的补充。的作用机制teriparatide独特之处在于,它具有合成属性,因此构建骨。自从teriparatide批准在美国2002年,大量的关于用于骨质疏松症发展兴趣。目的:本文综述了信息在新重组人甲状旁腺激素teriparatide (hPTH(猴)),包括其临床药理学、作用机制、药代动力学特性,临床疗效,安全性,潜在的药物相互作用,禁忌症和警告,剂量和管理和经济学。方法:本文中包含的文章被确定通过搜索PubMed和MEDLINE(1966 - 2003年12月)与国际制药抽象(1970 - 2003年1必威国际app2月)。必威国际app搜索条件包括teriparatide在内,重组人甲状旁腺激素(猴)和骨质疏松症。确定文章综述了额外的引用的出版物。具体产品信息也从teriparatide制造商获得。结果:Teriparatide研究在绝经后妇女骨质疏松症、药物引起的骨质疏松症(特别是类固醇诱导性骨质疏松症),和男性骨质疏松症。可用的数据从不同的临床试验显示增加骨密度(BMD)及骨矿物质含量(BMC)使用teriparatide与安慰剂相比。 One study found that women treated with the 20-microg dose and the 40-microg dose were 35% and 40%, respectively, less likely to have one or more new nonvertebral fractures compared with placebo (P = 0.02). Another study compared the use of daily teriparatide 40-microg injections versus oral daily alendronate. Results showed that the incidence of nonvertebral fractures was significantly lower in the teriparatide group than the alendronate group (P < 0.05). A study using 20- and 40-microg daily injections of teriparatide was performed in men with osteoporosis. There was a statistically significant increase in lumbar spine BMD of 5.9% in the 20-microg group and 9.0% in the 40-microg group (both, P < 0.001). In the femoral neck, a 1.5% increase in BMD occurred in the 20-microg group (P = 0.021) and a 0.9% increase in the 40-microg group (P < 0.001). A limited number of studies are available assessing the combination of antiresorptive medications and teriparatide; however, the available data suggest that the effects of teriperatide do not require prior stimulation of bone resorption. CONCLUSIONS: Teriparatide has been shown clinically to improve BMD and BMC in postmenopausal women and in men. Because of its anabolic capabilities, teriparatide can be used as an alternative to the traditional therapies that are currently available for the treatment of osteoporosis, with scheduled monitoring for adverse effects such as hypercalcemia and urinary calcium excretion. In 1 study, mild hypercalcemia was seen most often 4 to 6 hours after SC injection of teriparatide before returning to normal. Urinary calcium was observed to increase by 30 mg/d (0.75 mmol/d) with teriparatide.

DrugBank数据引用了这篇文章

药物